{"id":"W4386189439","doi":"10.1007/s40120-023-00533-1","title":"Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cégep de Lévis; Selkirk College","funders":"UCB Pharma; National Institutes of Health; Britannia Pharmaceuticals; H. Lundbeck A/S; Newcastle University; Eisai; University of Oxford; Wellcome Trust; Medical Research Council; International Parkinson and Movement Disorder Society; AbbVie; EVER Neuro Pharma; Ministero dell’Istruzione, dell’Università e della Ricerca; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Pfizer","keywords":"Medicine; Parkinson's disease; Open label; Neurology; Internal medicine; Pharmacology; Disease; Adverse effect; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002639728,0.0003341433,0.0006492732,0.0001736842,0.0001775887,0.00005914406,0.0001628093,0.0001265308,0.00004141055],"category_scores_gemma":[0.0001074661,0.0002827671,0.00004041636,0.0002222546,0.0001125667,0.00008287465,0.0001438374,0.0002662432,0.00002022652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001848816,"about_ca_system_score_gemma":0.00005906823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003617626,"about_ca_topic_score_gemma":0.0001807096,"domain_scores_codex":[0.9976553,0.0003369366,0.0004103438,0.0009569106,0.0001985732,0.0004419756],"domain_scores_gemma":[0.9985622,0.0004400585,0.0001194306,0.0004762167,0.00002918074,0.000372886],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4088813,0.04353305,0.2071772,0.00002342603,0.0008519224,0.05668695,0.002364798,0.000006933346,0.003573852,0.00008851663,0.0004941822,0.2763179],"study_design_scores_gemma":[0.1672554,0.03075895,0.7316625,0.00004928688,0.0002688056,0.0001545967,0.0001132693,0.0006172501,0.0001137116,0.0009149735,0.06770342,0.0003879069],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927374,0.002542328,0.000002291864,0.001722988,0.0002500377,0.001884263,0.0003628102,0.0001352709,0.0003625725],"genre_scores_gemma":[0.9947038,0.003207493,0.00002261969,0.001410723,0.00008612197,0.00009084148,0.0002080125,0.00004823063,0.0002222112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5244853,"threshold_uncertainty_score":0.9999624,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04677587415452242,"score_gpt":0.3153436746865626,"score_spread":0.2685678005320402,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}